Hepatocellular carcinoma (HCC) is a prototypical inflammation‑associated cancer, as approximately 90% of cases arise in the context of chronic hepatic inflammation. Cytokines of the IL‑1 family play a crucial role in both local and systemic inflammation. Three cytokines in this family—IL‑1, IL‑18, and IL‑33—have been linked to HCC development or growth through different mechanisms. Although these cytokines bind to distinct receptors, all three require the same co‑receptor, known as IL1RAP, to exert their biological functions. This provides an opportunity to inhibit the inflammatory actions of all three cytokines by targeting a single molecule. Therefore, we hypothesize that blocking IL1RAP could be a useful therapeutic strategy to reduce HCC progression or development, or to enhance the efficacy of current immunotherapies.
The specific aims (SA) of this proposal are: [SA1] to evaluate whether IL1RAP promotes HCC development in a ‘western diet’ (WD)–induced HCC model; [SA2] to assess whether IL1RAP blockade reduces HCC growth in a humanized model; [SA3] to analyze how IL1RAP shapes the tumor microenvironment (TME); [SA4] to determine whether IL1RAP blockade improves the response to immunotherapy in HCC; [SA5] to examine the impact of IL1RAP on the activity of cytotoxic T lymphocytes (CTLs) against patient‑derived tumor cells.
In summary, our objective is to investigate the role of this co‑receptor in HCC pathogenesis, the composition of the TME, and its potential use in combination therapy. To achieve this, we will employ relevant murine models (WD, humanized mice) and methodologies (scRNA‑seq, organoids, and in vivo interventions).

